Chemotherapy Clinical Trials in Shanghai
8 recruitingShanghai, China
Showing 1–8 of 8 trials
Recruiting
Phase 2
A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer
ChemotherapyctDNA
Fudan University100 enrolled1 locationNCT07562490
Recruiting
Phase 2
Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer
ctDNAColorectal Cancer (CRC)Adjuvant Chemotherapy
Fudan University80 enrolled1 locationNCT07562659
Recruiting
Phase 2
Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer
ChemotherapyctDNA
Fudan University340 enrolled1 locationNCT07562711
Recruiting
Phase 2
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)+2 more
AstraZeneca257 enrolled59 locationsNCT06535607
Recruiting
Phase 2
Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors
Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors
Changhai Hospital40 enrolled1 locationNCT07492693
Recruiting
Phase 3
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Gastric Cancer (GC)Adjuvant ChemotherapyOxaliplatin+2 more
Ruijin Hospital387 enrolled5 locationsNCT07366528
Recruiting
Phase 2
Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer
Cervical CancerRadiotherapyNeoadjuvant Chemotherapy+1 more
Shanghai Jiao Tong University Affiliated Sixth People's Hospital36 enrolled1 locationNCT05554276
Recruiting
Phase 2
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
Chemotherapy, Adjuvant
Shanghai Pulmonary Hospital, Shanghai, China460 enrolled1 locationNCT03351842